TQB2103 / Sino Biopharm - LARVOL DELTA

First in human phase I study of TQB2103, a Claudin18.2 (CLDN18.2) targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors. (ASCO 2025) - P1 | "TQB2103 demonstrated encouraging anti-tumor activity in CLDN18.2 positive solid tumors, with a favorable safety profile. The findings support further development of TQB2103 monotherapy or in combination with other anti-cancer therapies."

Clinical • Metastases • P1 data • Anemia • Biliary Cancer • Biliary Tract Cancer • Gastric Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18

Clinical Trial Evaluating the Safety of the TQB2103 for Injection (clinicaltrials.gov) - P1 | N=71 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

Clinical Trial Evaluating the Safety of the TQB2103 for Injection (clinicaltrials.gov) - P1 | N=71 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor